Extended Data Fig. 5: Clinical indicators during phage treatment. | Nature Medicine

Extended Data Fig. 5: Clinical indicators during phage treatment.

From: Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection

Extended Data Fig. 5

Safety assessments during phage treatment included regular monitoring of complete blood counts with differential, comprehensive metabolic panels, and inflammatory markers. During six-months of intravenous phage treatment there were no clinically significant differences observed in a, white blood cell (WBC) total counts and differentials, b, hemoglobin and platelets, c, liver function (alanine transaminase, ALT; aspartate transaminase, AST; and total bilirubin) or kidney function (creatinine), and d, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).

Back to article page